Therapy-related myelodysplastic syndrome (t-MDS)/ acute myeloid leukemia (t-AML) has been reported after autologous bone marrow or peripheral blood stem cell transplantation (ABMT/PBSCT) for various malignancies. We retrospectively reviewed all adult ABMT/PBSCT cases performed at the University of Chicago Medical Center from 1985 to 1997 in order to determine the incidence of therapy-related leukemia. Among 649 patients, seven (1.1%) developed therapyrelated acute lymphoblastic leukemia (one patient) or t-MDS/t-AML (six patients). Of these seven, primary malignancies included one case of breast carcinoma, five cases of Hodgkin's disease (HD) and one case of nonHodgkin's lymphoma (NHL). Disease-specific incidences for therapy-related leukemia occurring after ABMT/PBSCT were one in 354 (0.3%) for breast carcinoma, five in 79 (6.3%) for HD and one in 103 (1%) for NHL. The median latency periods for the development of therapy-related leukemia from the time of initial diagnosis and of ABMT/PBSCT were 5.5 and 1.5 years, respectively, for the combined HD and NHL group of patients and 4.4 and 2.8 years, respectively, for the one breast carcinoma patient. All seven patients had clonal cytogenetic abnormalities, and five had recurring abnormalities typical of myeloid disorders. Given the similar latency period observed in patients treated with conventional chemotherapy alone, our findings support the hypothesis that therapy-related leukemia after ABMT/PBSCT likely results from pre-transplant therapy. Early detection of therapy-related leukemia is therefore critical to exclude these patients from undergoing ABMT/PBSCT. Keywords: therapy-related leukemia; autologous bone marrow/peripheral blood stem cell transplantation; cytogenetics Autologous bone marrow or peripheral blood stem cell transplantation (ABMT/PBSCT) is widely used for the treatment of many different malignancies. Therapy-related Correspondence: Dr RM Sobecks, The University of Chicago Medical Center, 5841 S Maryland Ave, MC2115, Chicago IL, 60637-1470, USA Received 8 October 1998; accepted 6 January 1999 myelodysplastic syndrome (t-MDS)/acute myeloid leukemia (t-AML) has been described after ABMT/PBSCT and most experiences have involved leukemia arising after treatment for Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL).
myelodysplastic syndrome (t-MDS)/acute myeloid leukemia (t-AML) has been described after ABMT/PBSCT and most experiences have involved leukemia arising after treatment for Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL). [1] [2] [3] [4] More recently, t-MDS/t-AML after ABMT/PBSCT has been reported in patients treated for breast carcinoma, 5, 6 multiple myeloma 7 and metastatic seminoma. 8 These reports suggest that t-MDS/t-AML results from chemotherapy and/or radiation therapy given for the primary malignancy prior to transplant rather than from the actual high-dose chemotherapy administered for the transplant preparative regimen. This hypothesis is supported by the time interval required for the disease to develop in ABMT/PBSCT patients (approximately 4 to 6 years after initial diagnosis). [1] [2] [3] [4] This duration is similar to that observed for t-MDS/t-AML following conventional-dose chemotherapy. 9, 10 In contrast, the time from ABMT/PBSCT to the diagnosis of t-MDS/t-AML is substantially less (median, 2.7 years). [1] [2] [3] [4] Most cases of therapy-related leukemia are myeloid. However, therapy-related acute lymphoblastic leukemia (t-ALL) occurs in some cases. The term therapy-related leukemia will be used herein to refer to t-MDS/t-AML as well as t-ALL. We report our institution's experience of secondary MDS and leukemia after high-dose chemotherapy and ABMT/PBSCT for various malignancies. Our analysis includes detailed cytogenetic evaluation.
Patients and methods

Patients
From 1985 to 1997, a total of 649 adult patients underwent ABMT/PBSCT at the University of Chicago Medical Center. Based on a review of our Bone Marrow Transplant Database (Chicago, IL, USA), the following clinical characteristics were collected for patients who developed therapy-related leukemia: age at time of transplant, sex, disease histology and stage, pre-transplant treatment regimens and radiation therapy (including total dose and fields involved), type of transplant (ABMT or PBSCT), preparative regimen, post-transplant consolidative radiation therapy, response after transplant, time from initial diagnosis to transplant and to the development of therapy-related leukemia, and post-transplant clinical outcome. All patients continued to be followed after ABMT/PBSCT and none were lost to follow-up. Bone marrow morphology was based on both marrow aspirate and trephine morphology. Pre-transplant bone marrow examinations for all patients were usually performed 2-3 months prior to transplant. Morphology review for all patients was without evidence of MDS or acute leukemia. Bone marrow cytogenetic analysis was not performed routinely prior to transplant.
Treatment regimens
The transplant preparative regimen for patients was determined by their diagnosis, response to prior therapy and the disease-specific treatment protocol available at the time of transplantation. Table 1 demonstrates each patients transplant preparative regimen. All treatment protocols were approved by the University of Chicago institutional review Table 1 Clinical characteristics and prior treatment for patients with therapy-related leukemia post-ABMT/PBSCT Cy = cyclophosphamide; Thi = thiotepa; E = etoposide; Mit = mitoxantrone; Dex = dexamethasone; VCR = vincristine; Cis = cisplatin; IFN = interferonalpha; AraC = cytarabine; RT = radiation therapy; CAF = cyclophosphamide, doxorubicin, fluorouracil; MOPP = mechlorethamine, vincristine, procarbazine and prednisone; ABVD = doxorubicin, bleomycin, vinblastine and dacarbazine; EVA = etoposide, vinblastine and doxorubicin; COMLA = cyclophosphamide, vincristine, methotrexate, leucovorin and cytarabine; PAV = procarbazine, adriamycin and vinblastine; LOMAC = leucovorin, vincristine, methotrexate, doxorubicin and cyclophosphamide; DHAP = dexamethasone, cytarabine and cisplatin; MC = mantle cell NHL; HD = Hodgkin's disease; BM = bone marrow; PBSC = peripheral blood stem cells; CR = complete response; PR = partial response. board and all patients signed informed consent prior to ABMT/PBSCT.
Therapy-related leukemia
Patients were closely followed after ABMT/PBSCT and bone marrow examinations were performed routinely on patients suspected of having developed therapy-related leukemia (ie patients whose blood counts did not recover posttransplant or patients who developed cytopenias). Cases were classified according to the FAB classification system when possible or as refractory cytopenia with multilineage dysplasia (RCMD) 11 when appropriate. Cytogenetic analysis using a trypsin-Giemsa banding technique was performed on cells from aspirated bone marrow, bone marrow biopsy specimens and/or peripheral blood samples obtained at the time of secondary bone marrow dysfunction. Meta-phase cells from short-term (24 and 48 h) unstimulated cultures were examined. Chromosomal abnormalities are described according to the International System for Human Cytogenetic Nomenclature (ISCN, 1995).
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Results
Of 649 patients who received ABMT or PBSCT, seven (1.1%) subsequently developed MDS or leukemia. This included one patient with breast carcinoma, five patients with Hodgkin's disease and one patient with NHL. The overall incidence of MDS or leukemia post-transplant was one in 354 (0.3%) breast carcinoma patients, five in 79 (6.3%) Hodgkin's disease patients, and one in 103 (1%) NHL patients. No cases of therapy-related leukemia were observed among the remaining 113 ABMT/PBSCT patients who had diagnoses of multiple myeloma, ovarian carcinoma, or various other solid tumors. Patient characteristics, treatment and outcome are described in Tables 1 and 2 .
Breast carcinoma
Patient 1 had metastatic breast carcinoma and had achieved a complete remission post-ABMT with no evidence of disease recurrence. However, 34 months post-transplant she developed CD10-positive acute lymphoblastic leukemia with a hyperdiploid karyotype (Ͼ50 chromosomes). After a standard induction, intensification and maintenance Table 2 Post-ABMT/PBSCT presentation of therapy-related leukemia chemotherapy regimen for ALL, she remained in complete remission for 24 months. She then developed relapsed ALL and subsequently underwent an allogeneic bone marrow transplant using total body irradiation and high-dose etoposide as the preparative regimen. This patient died 1 month post-allogeneic transplant of respiratory and hepatic failure.
Hodgkin's disease
The median age at the time of transplant for the five Hodgkin's disease patients who developed therapy-related leukemia was 32 years (range, 32-36). These patients received a median of two chemotherapy regimens prior to transplant (range, 2-3) and three patients received radiation therapy as well (see Table 1 ). Four of the patients (2, 3, 5 and 6) achieved a complete remission post-ABMT/PBSCT. Three of these four later developed recurrent disease at a median of 19 months post-transplant (range, 19-28 months).
Patient 2 received salvage chemotherapy for relapsed Hodgkin's disease post-PBSCT with etoposide, vinblastine and doxorubicin (EVA) followed by three cycles of mesna, ifosfamide, mitoxantrone and etoposide (MINE). She died 5 months later with congestive heart failure, t-MDS and progressive HD. Patient 3 had recurrent HD in his bone marrow at the time that t-MDS was diagnosed. He subsequently received cytarabine and daunorubicin followed by a clinical trial with vincristine in which stellazine and verapamil were employed as potential modulators of multidrug resistance. He died of an infectious pneumonitic pro-cess with possible progressive HD 4 months post relapse (no autopsy was performed). Patient 4 died of progressive HD 27 months post-PBSCT. Patient 5 developed a disseminated varicella zoster infection 3 years post-ABMT and died of probable sepsis. Patient 6 developed recurrent HD limited to a right cervical lymph node. However, he died 4 months later after having developed nocardia, cytomegalovirus and Enterococcus faecium pneumonia with subsequent multiorgan system failure.
Three of the five HD patients (2, 3 and 5) had characteristic cytogenetic abnormalities with loss or deletions of chromosomes 5 and/or 7 ( Table 2 ). The other two HD patients (4 and 6) had clonal abnormalities detected: t(4;14) and t(10;?16) for patient 4, and monosomy 13 for patient 6. No patient had a translocation involving 11q23 which occur in t-AML after treatment with topoisomerase II inhibitors.
The median times from initial diagnosis to ABMT/PBSCT and to therapy-related leukemia were 45 months (range, 20-116 months) and 64 months (range, 37-134 months), respectively. The median overall survival for the HD patients was 27 months post transplant (range, 23-47 months) and 4 months after developing therapy-related leukemia (range, 2-9 months).
Non-Hodgkin's lymphoma
One patient had mantle cell NHL (patient 7, Table 1 ) and developed t-MDS 2 months post-transplant. He died 12 months later after developing a recurrence of his primary lymphoma which transformed to a blastic variant with leukemic manifestations concurrent with t-MDS. This patient had a translocation involving 21q22, which has been observed in a small subset of t-MDS/t-AML (approximately 3%).
Discussion
The risk of t-MDS/t-AML has increased with further follow-up time after ABMT/PBSCT. Reported crude incidence rates range from 2.3-7.6% for HD and NHL patients [1] [2] [3] [4] and 0.6-5.7% for breast carcinoma patients. 5, 6 Our series demonstrates a relatively low overall incidence (1.1%) of therapy-related leukemia after ABMT/PBSCT; however, the incidence for our HD patients (6.3%) was comparable to prior experiences. [1] [2] [3] [4] In our HD and NHL patients, the median latency periods for the development of t-MDS/t-AML from the time of initial diagnosis and from the time of ABMT/PBSCT were similar to those in earlier reports. [1] [2] [3] [4] From the time of initial diagnosis we observed a 5.5 year median latency period (range, 4.3-11.2 years) as compared with 5.5 years (range, 3.9-5.8 years) in other series. After ABMT/PBSCT, our patients had a median latency period of 1.5 years (range, 0.2-3.8 years) while that of other institutions was 2.7 years (range, 1.4-3.7 years).
The development of t-MDS/t-AML has recently been recognized post-ABMT/PBSCT for breast carcinoma. 5, 6 Laughlin et al 5 reported five patients, one of whom had a poor-risk cytogenetic abnormality [del(7q)]. The 4-year probability of developing t-MDS/t-AML was 1.6%. Median latency periods from the time of initial therapy and from ABMT to the diagnosis of t-MDS/t-AML were 47 months (range, 26-71 months) and 28 months (range, 2-41 months), respectively. Median survival after the diagnosis of t-MDS/t-AML was 9 months. Roman-Unfer et al 6 identified two breast carcinoma patients who developed t-MDS/t-AML after ABMT, both of whom had recurring cytogenetic abnormalities (one patient with an 11q23 translocation and one patient with a del(5q)). The median latency period for the development of t-MDS/t-AML post-ABMT was 15.5 months (range, 8-23 months) .
The single patient treated for breast carcinoma in our series developed ALL. This patient was included in our report since she developed a leukemia post-ABMT. In addition, therapy-related ALL has been described previously in breast carcinoma patients after treatment with prior doxorubicin-containing regimens. 13 However, therapy-related ALL has thus far only been clearly established in the setting of 11q23 translocations (MLL rearrangement). Thus our patient's leukemia may well have been a second primary malignancy rather than therapy-related disease. Though she did not have an 11q23 translocation, the latency periods from the time of initial diagnosis and from ABMT to the development of her leukemia (53 and 34 months, respectively) were comparable to those reported by Laughlin et al 5 (see above). Of note, the time period from initial diagnosis is shorter for breast carcinoma patients than for HD and NHL patients (47-53 months vs 66 months, respectively), whereas the latency period from ABMT to therapy-related leukemia is similar (15.5-34 months vs 18-32.4 months, respectively). This earlier occurrence of therapy-related leukemia in breast carcinoma patients may be due to the small patient numbers in the reported series.
Investigators at the University of Arkansas reported 188 multiple myeloma patients, 71 of whom were enrolled in a total therapy program which allowed no more than one cycle of prior standard chemotherapy (median duration of pre-transplant therapy was 7.6 months). 7 The remaining 117 patients had more prolonged pretransplant chemotherapy (median, 24 months). Therapy-related MDS developed in seven patients from the latter group, whereas no cases were observed among the 'total therapy' group of patients with limited prior standard chemotherapy. These investigators concluded that pretransplant therapy was the main risk factor for t-MDS post-autologous transplantation in multiple myeloma. Among 28 multiple myeloma patients at our institution no cases of therapy-related leukemia were identified after PBSCT. Similar to the 'total therapy' group from the University of Arkansas series, most of our patients had received three cycles of vincristine, doxorubicin and dexamethasone, followed by high-dose cyclophosphamide for stem cell mobilization and one cycle of EDAP (etoposide, dexamethasone, cytarabine and cisplatin) prior to transplant.
14 However, several of our patients had also received additional prior therapy including melphalan.
All seven patients in this report had clonal cytogenetic abnormalities. Patient 1 with therapy-related ALL had a hyperdiploid karyotype with Ͼ50 chromosomes, a recurring abnormality in ALL. Of the six patients with t-MDS/t-AML, five had a recurring abnormality typical of myeloid disorders. In particular, three patients (2, 3 and 5) had loss or deletion of chromosome 5 and/or 7, characteristic of t-AML arising after alkylating agent therapy, and one (patient 7) had a translocation involving 21q22, characteristic of t-AML arising after therapy with topoisomerase II inhibitors. Patient 6 had loss of chromosome 13. Overall, the cytogenetic pattern of these t-MDS/AML cases arising after ABMT/PBSCT is similar to that observed in our series of patients with t-MDS/AML occurring after cytotoxic therapy alone.
In our recently updated series of 270 consecutive patients with t-MDS/t-AML, 252 (93%) had a clonal chromosomal abnormality (Ref. 15 and Le Beau et al, unpublished) , and 191 patients (71%) had a clonal abnormality leading to loss or deletion of chromosome 5 and/or 7. Overall, 115 patients (42%) had abnormalities of chromosome 5, and 138 (51%) had abnormalities of chromosome 7. Nine patients (3.3%) had a translocation of 11q23, and eight (2.9%) patients had a translocation of 21q22. Three patients (1%) had −13 or del(13q).
Our current report supports the hypothesis that therapyrelated leukemia after ABMT/PBSCT likely results from pre-transplant therapy. However, the high-dose chemotherapy may have had a contributory role since no patient had evidence of therapy-related leukemia immediately prior to ABMT/PBSCT. Since the use of ABMT/PBSCT will probably continue to increase in the future, therapy-related leukemia will remain a significant post-transplant risk. Recognizing those patients with evidence of therapy-related leukemia prior to transplant is important in order to exclude them from undergoing ABMT/PBSCT. As in the case of HD, 16 routine bone marrow cytogenetic analysis prior to ABMT/PBSCT may allow early detection. This should be considered particularly for those patients extensively treated prior to their transplant. In addition, patients should have ABMT/PBSCT performed earlier in their disease course, or at least have their blood stem cells harvested before being heavily pretreated. Finally, further efforts in the treatment of therapy-related leukemia are clearly warranted given the uniformly poor outcome of these patients.
